UBS Group
EWTX icon

UBS Group’s Edgewise Therapeutics EWTX Stock Holding History

UBS Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.11M Sell
174,967
-1,136,158
-87% -$39.2M ﹤0.01% 3817
2026
Q1 		$41.3M Sell
1,311,125
-805,948
-38% -$23.2M 0.01% 1841
2025
Q4 		$52.5M Buy
2,117,073
+2,002,945
+1,755% +$40.2M 0.01% 1568
2025
Q3 		$1.85M Sell
114,128
-56,854
-33% -$806K ﹤0.01% 5027
2025
Q2 		$2.24M Sell
170,982
-72,914
-30% -$1.05M ﹤0.01% 4694
2025
Q1 		$5.37M Buy
243,896
+151,830
+165% +$3.98M ﹤0.01% 3714
2024
Q4 		$2.46M Buy
92,066
+16,761
+22% +$534K ﹤0.01% 4532
2024
Q3 		$2.01M Buy
75,305
+14,795
+24% +$294K ﹤0.01% 3985
2024
Q2 		$1.09M Sell
60,510
-13,608
-18% -$237K ﹤0.01% 4341
2024
Q1 		$1.35M Buy
+74,118
New +$1.18M ﹤0.01% 4337
2023
Q1 		– Sell
-1,551
Closed -$13.9K – 9795
2022
Q4 		$13.9K Buy
+1,551
New +$14.5K ﹤0.01% 8126
2022
Q2 		– Sell
-22,047
Closed -$214K – 10477
2022
Q1 		$214K Buy
+22,047
New +$284K ﹤0.01% 5298
2021
Q3 		– Sell
-868
Closed -$19K – 9686
2021
Q2 		$19K Buy
+868
New +$23.7K ﹤0.01% 7381

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's EWTX Position: Q2 2026 in Review

UBS Group reduced its Edgewise Therapeutics (EWTX) stake by 87% in Q2 2026, selling an estimated $39.2M and leaving 174,967 shares worth $7.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

UBS Group first reported a position in EWTX in Q2 2021 and has held it in 13 quarters since. The position peaked at $52.5M in Q4 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • UBS Group held 174,967 shares of Edgewise Therapeutics worth $7.11M as of Q2 2026.
  • UBS Group sold 1,136,158 Edgewise Therapeutics shares in Q2 2026, an estimated $39.2M.
  • Edgewise Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3817 holding.
  • UBS Group first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • UBS Group's Edgewise Therapeutics position peaked at $52.5M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.